Literature DB >> 7486897

Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations.

S Ouabdesselam1, D C Hooper, J Tankovic, C J Soussy.   

Abstract

Twelve quinolone-resistant clinical isolates of Escherichia coli (nalidixic acid MICs, 64 to 512 micrograms/ml; norfloxacin MICs, 0.25 to 8 micrograms/ml) were transformed with plasmid pJSW101 carrying the gyrA+ gene and with plasmid pJB11 carrying the gyrB+ gene to examine the proportion of gyrA and gyrB mutations. Transformation with pJSW101 resulted in complementation (nalidixic acid MICs, 4 to 32 micrograms/ml; norfloxacin MICs, 0.06 to 0.25 micrograms/ml). In contrast, no change in MICs were observed after transformation with pJB11. A 418-bp fragment of gyrA from the 12 strains was amplified by PCR. Direct DNA sequencing of that fragment identified the causes of quinolone resistance in eight strains as a single point mutation leading to a substitution of the serine at position 83 (Ser-83) to Leu and in four strains as a single point mutation leading to a substitution of Asp-87 to Gly. Exchange of the fragment from one of these strains with that of gyrA+ and transformation of resistance with the hybrid gyrA plasmid indicated the contribution of Gly-87 to resistance and the stabilities of mutants containing GyrA (Gly-87). Thus, gyrA gene mutations are probably encountered more often than gyrB gene mutations in clinical isolates of E. coli. In addition, the substitution of Asp-87 to Gly can be encountered in such strains. On the basis of the level of resistance found in the fragment exchange experiment, the quinolone resistance attributable to Gly-87 appears to be comparable to that attributable to Leu-83. The levels of resistance found in the clinical isolates shown to have a Gly-87 mutation (nalidixic acid MICs, 64 to 512 micrograms/ml; norfloxacin MICs, 0.5 to 4 micrograms/ml) suggest that the Gly-87 mutation causes resistance at the level of the nalidixic acid MIC (64 micrograms/ml) or the norfloxacin MIC (0.5 micrograms/ml or less) and that the additional increments in resistance seen in the other strains with higher levels of resistance may be attributable to additional mutations. The single-strand conformational polymorphism analysis with PCR products readily detected te Leu-83 and Gly-87 mutations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7486897      PMCID: PMC162804          DOI: 10.1128/AAC.39.8.1667

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

Review 1.  Mechanisms of resistance to quinolones and clinical perspectives.

Authors:  L J Piddock; R Wise
Journal:  J Antimicrob Chemother       Date:  1989-04       Impact factor: 5.790

2.  gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli.

Authors:  S Nakamura; M Nakamura; T Kojima; H Yoshida
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

3.  High efficiency transformation of E. coli by high voltage electroporation.

Authors:  W J Dower; J F Miller; C W Ragsdale
Journal:  Nucleic Acids Res       Date:  1988-07-11       Impact factor: 16.971

4.  Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction.

Authors:  S P Cohen; L M McMurry; D C Hooper; J S Wolfson; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

5.  Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli.

Authors:  D C Hooper; J S Wolfson; K S Souza; C Tung; G L McHugh; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

Review 6.  Bacterial resistance to quinolones: mechanisms and clinical importance.

Authors:  J S Wolfson; D C Hooper
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

7.  Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones.

Authors:  M E Cullen; A W Wyke; R Kuroda; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

9.  Quinolone-resistant mutations of the gyrA gene of Escherichia coli.

Authors:  H Yoshida; T Kojima; J Yamagishi; S Nakamura
Journal:  Mol Gen Genet       Date:  1988-01

10.  Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation.

Authors:  D C Hooper; J S Wolfson; K S Souza; E Y Ng; G L McHugh; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

View more
  25 in total

Review 1.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Development of a rapid assay for detecting gyrA mutations in Escherichia coli and determination of incidence of gyrA mutations in clinical strains isolated from patients with complicated urinary tract infections.

Authors:  S Ozeki; T Deguchi; M Yasuda; M Nakano; T Kawamura; Y Nishino; Y Kawada
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

3.  In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.

Authors:  Laurel S Almer; Jennifer B Hoffrage; Erika L Keller; Robert K Flamm; Virginia D Shortridge
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

4.  Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae.

Authors:  Annie Canu; Brigitte Malbruny; Maëlle Coquemont; Todd A Davies; Peter C Appelbaum; Roland Leclercq
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

5.  Characterization of fluoroquinolone resistance among veterinary isolates of avian Escherichia coli.

Authors:  D G White; L J Piddock; J J Maurer; S Zhao; V Ricci; S G Thayer
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

6.  Novel combination of mutations in the DNA gyrase and topoisomerase IV genes in laboratory-grown fluoroquinolone-resistant Shigella flexneri mutants.

Authors:  Y W Chu; E T Houang; A F Cheng
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains.

Authors:  T Wang; M Tanaka; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

8.  Nonradioactive single-strand conformation polymorphism analysis for detection of fluoroquinolone resistance in mycobacteria.

Authors:  W Sougakoff; N Lemaître; E Cambau; M Szpytma; V Revel; V Jarlier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-05       Impact factor: 3.267

9.  Comparison of agar dilution, disk diffusion, MicroScan, and Vitek antimicrobial susceptibility testing methods to broth microdilution for detection of fluoroquinolone-resistant isolates of the family Enterobacteriaceae.

Authors:  C D Steward; S A Stocker; J M Swenson; C M O'Hara; J R Edwards; R P Gaynes; J E McGowan; F C Tenover
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

10.  Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli.

Authors:  P Heisig
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.